Hizentra Liquid
NDC Package 44206-451-01
Package Information
Hizentra (human immunoglobulin g) liquids is a medication used to boost the body's natural defense system against infection in persons with a weakened immune system (primary immune deficiency). This formulation utilizes a liquid delivery system. Marketed by Csl Behring Ag, this product is identified by NDC 44206-451 and is authorized under FDA application BLA125350.
Identification & Billing
- RxCUI: 1809061 - immunoglobulin G, human 20 % in 50 ML Injection
- RxCUI: 1809061 - 50 ML immunoglobulin G, human 200 MG/ML Injection
- RxCUI: 1809061 - immunoglobulin G, human 10 GM per 50 ML Injection
- RxCUI: 1809061 - immunoglobulin G, human 20 % per 50 ML Injection
- RxCUI: 1809063 - Hizentra 20 % in 50 ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 44206 - Csl Behring Ag
- 44206-451 - Hizentra
- 44206-451-01 - 1 VIAL, SINGLE-DOSE in 1 CARTON / 5 mL in 1 VIAL, SINGLE-DOSE (44206-451-90)
- 44206-451 - Hizentra
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 44206-451-01 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 5 ml in 1 vial, single-dose (44206-451-90) of Hizentra, a plasma derivative labeled by Csl Behring Ag. This liquid is formulated for subcutaneous use and contains human immunoglobulin g as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Csl Behring Ag on October 03, 2011. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to boost the body's natural defense system against infection in persons with a weakened immune system (primary immune deficiency). Immune globulin contains natural substances called antibodies (a type called IgG) that come from healthy human blood (plasma). These antibodies help protect your body against infections and help you to fight an infection if you get sick. Some immune globulin products may also be used to treat a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP).
How is this Csl Behring Ag product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 44206045101. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
